Skip to content

The PROspective German NOn-CF bronchiectaSIS Patient Registry

The PROspective German NOn-CF bronchiectaSIS Patient Registry

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02574143
Acronym
PROGNOSIS
Enrollment
750
Registered
2015-10-12
Start date
2015-07-31
Completion date
2021-07-31
Last updated
2020-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiectasis

Keywords

Prognosis, Prospective Study, Quality of Life, Radiology, Rehabilitation, Registry;, Signs and Symptoms, Therapy, Bronchiectiasis, Diagnosis, Epidemiology, Etiology, Longitudinal Study, Microbiology

Brief summary

The purpose of this study is to study the epidemiology of non-CF bronchiectasis (NCFB) and to provide an estimate of the distribution (prevalence) of NCFB etiologies across all different levels of health care as well as real-life data regarding the current management of NCFB in Germany.

Detailed description

* To study the epidemiology of non-CF bronchiectasis (NCFB) and to provide an estimate of the distribution (prevalence) of NCFB etiologies across all different levels of health care as well as real-life data regarding the current management of NCFB in Germany * To establish feasible investigational strategies in order to establish the etiology of NCFB * To perform observational research into bronchiectasis, particularly in areas where single center datasets are underpowered, such as in rare etiologies or determining markers of prognosis * To promote collaborative clinical, basic and translational research in NCFB between German (and European) centers * To provide a registry of well phenotyped patients with NCFB in clinical centers potentially eligible for enrolment into clinical trials * To track access to healthcare and cost of caring for patients with NCFB over time

Interventions

None listed

Sponsors

CAPNETZ Stiftung
CollaboratorOTHER
German Center for Lung Research
CollaboratorOTHER
Hannover Medical School
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* A clinical history consistent with bronchiectasis * (High resolution) computed tomography (CT) scan of the chest demonstrating bronchiectasis affecting 1 or more lobes

Exclusion criteria

* Bronchiectasis due to known cystic fibrosis (CF) * Age \<18 years * Interstitial lung disease * Prior lung or heart-lung transplantation

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with non-CF bronchiectasis (NCFB) across all different levels of health care regarding the current management of NCFB in Germanythree yearsTo establish a national, representative, prospective, observational and longitudinal NCFB database and collaborative research network with a database including a minimum of 750 patients from a minimum of 25 centers from all levels of healthcare across Germany after a period of 3 years.

Secondary

MeasureTime frameDescription
Prevalence of non-CF bronchiectasis (NCFB) etiologies (composite outcome measures) across all different levels of health carethree years* Distribution (prevalence) of underlying conditions/etiologies * Clinical presentation of NCFB * Predictors of lung function decline in patients with NCFB * Diagnostics employed in determining the etiology of NCFB * Microbiology of NCFB * Radiology of NCFB * Comorbidity in patients with NCFB * Impact of exacerbations and hospitalizations on the clinical course of NCFB * Prescription patterns of pharmacological respiratory treatments for NCFB * Usage and benefit of surgical procedures in NCFB * Physical therapy and rehabilitation * Healthcare utilization and associated costs in NCFB * QOL(Questions of Life) among patients with NCFB * survival/mortality of NCFB

Countries

Germany

Contacts

Primary ContactGrit Barten
prognosis@capnetz.de+49 511 5324434

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026